¥3,577.00
3.69% today
Tokyo, Dec 03, 07:14 am CET
Why the stock moved Why the stock moved Beta
ISIN
JP3475350009
Symbol
4568
Index

DAIICHI SANKYO Stock price

¥3,561.00
-108.00 2.94% 1M
-141.00 3.81% 6M
-791.00 18.18% YTD
-1,365.00 27.71% 1Y
-758.00 17.55% 3Y
+50.00 1.42% 5Y
+2,685.83 306.89% 10Y
+2,816.00 377.99% 20Y
Tokyo, Closing price Wed, Dec 03 2025
-153.00 4.12%
ISIN
JP3475350009
Symbol
4568
Index
Industry

New AI Insights on DAIICHI SANKYO Insights AI Insights on DAIICHI SANKYO

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
¥7.1t
Enterprise Value
¥6.7t
Net debt
positive
Cash
¥593.6b
Shares outstanding
1.9b
Valuation (TTM | estimate)
P/E
24.6 | 21.3
P/S
3.6 | 3.4
EV/Sales
3.4 | 3.2
EV/FCF
negative
P/B
4.3
Dividends
DPS
¥78.00
Yield 1Y | 5Y
2.1% | 1.3%
Growth 1Y | 5Y
30.0% | 23.6%
Payout 1Y | 3Y
38.5% | 44.1%
Increased
4 Years
Financials (TTM | estimate)
Revenue
¥2.0t | ¥2.1t
EBITDA
¥361.3b | ¥451.2b
EBIT
¥289.3b | ¥28.2t
Net Income
¥279.9b | ¥322.3b
Free Cash Flow
¥-68.8b
Growth (TTM | estimate)
Revenue
12.6% | 11.3%
EBITDA
-1.8% | 12.6%
EBIT
-4.7% | 8,402.0%
Net Income
11.8% | 9.0%
Free Cash Flow
-116.6%
Margin (TTM | estimate)
Gross
76.2%
EBITDA
18.3% | 21.5%
EBIT
14.6%
Net
14.1% | 15.4%
Free Cash Flow
-3.5%
Financial Health
Equity Ratio
47.0%
Return on Equity
18.2%
ROCE
10.7%
ROIC
11.2%
Debt/Equity
0.1
More
EPS
¥151.2
FCF per Share
¥-37.2
Short interest
-
Employees
19k
Rev per Employee
¥100.7m
Show more

Is DAIICHI SANKYO a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,086 stocks worldwide.

DAIICHI SANKYO Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a DAIICHI SANKYO forecast:

20x Buy
95%
1x Hold
5%

Analyst Opinions

21 Analysts have issued a DAIICHI SANKYO forecast:

Buy
95%
Hold
5%

Financial data from DAIICHI SANKYO

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,978,882 1,978,882
13% 13%
100%
- Direct Costs 471,047 471,047
12% 12%
24%
1,507,835 1,507,835
13% 13%
76%
- Selling and Administrative Expenses 763,275 763,275
10% 10%
39%
- Research and Development Expense 460,310 460,310
17% 17%
23%
361,302 361,302
2% 2%
18%
- Depreciation and Amortization 72,040 72,040
12% 12%
4%
EBIT (Operating Income) EBIT 289,262 289,262
5% 5%
15%
Net Profit 279,895 279,895
12% 12%
14%

In millions JPY.

Don't miss a Thing! We will send you all news about DAIICHI SANKYO directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Hiroyuki Okuzawa
Employees 18,726
Founded 2005
Website www.daiichisankyo.co.jp

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today